Aura Biosciences/AURA

$8.74

-1.68%
-
1D1W1MYTD1YMAX

About Aura Biosciences

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing virus-like drug conjugates (VDCs), a novel class of therapies for the treatment of multiple oncology indications. The Company’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 consists of human papillomavirus (HPV)-derived VLP conjugated to hundreds of infrared laser-activated molecules. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is in development for ocular cancers and has initiated activities for the global Phase III trial evaluating first-line treatment of early-stage choroidal melanoma. It seeks to develop AU-011 across its ocular oncology franchise. In addition, the Company is developing AU-011 across multiple cancers, including in patients with non-muscle invasive bladder cancer.

Ticker

AURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Elisabet de los Pinos

Employees

70

Headquarters

Boston, United States

Aura Biosciences Metrics

BasicAdvanced
$436.38M
Market cap
-
P/E ratio
-$1.95
EPS
-
Beta
-
Dividend rate

What the Analysts think about Aura Biosciences

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
126.54% upside
High $21.00
Low $19.00
$8.74
Current price
$19.80
Average price target

Aura Biosciences Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-18.5M
1.65%
Profit margin
0%
-

Aura Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.83%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.55
-$0.46
-$0.48
-$0.48
-
Expected
-$0.52
-$0.54
-$0.49
-$0.52
-$0.41
Surprise
5.26%
-14.87%
-1.96%
-7.83%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Aura Biosciences stock

Buy or sell Aura Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing